MedPath

Evaluating the Safety and Efficacy of Telemedicine Neurology Assessments on a Mobile Stroke Unit

Not Applicable
Active, not recruiting
Conditions
Intracerebral Hemorrhage
Ischemic Stroke
Interventions
Other: In-Person Assessment by an Onboard Neurologist
Other: Telemedicine Assessment by Remote Neurologist
Registration Number
NCT05991310
Lead Sponsor
Melbourne Health
Brief Summary

The goal of this clinical trial is to compare a telemedicine neurologist staffing model to a traditional on-board model in patients being assessed for suspected acute stroke on a mobile stroke unit.

Detailed Description

This study is a prospective randomized mobile stroke unit trial comparing two staffing models: 1) a neurologist reviewing the patient via telemedicine (intervention) versus 2) an onboard neurologist assessing the patient in-person (comparator). Daily periods of remote (telemedicine) or in person (onboard) neurologist assessments will be randomly determined using an adaptive design.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
270
Inclusion Criteria
  1. Adults >=18 years of age
  2. Presenting within 24 hours of symptom onset or last known well.
  3. Patients assessed by MSU without cancellation (either by the local ambulance team or by MSU) prior to attending the patient.
Exclusion Criteria
  1. Attendance of the Melbourne MSU is deemed unnecessary by either the local paramedic team or the MSU team based on provided information prior to arrival on scene.
  2. The patient presents significant medical or logistical challenges which greatly delay standard treatment.
  3. Any other medical contraindication at the discretion of the investigator.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
In-Person Assessment by an Onboard NeurologistIn-Person Assessment by an Onboard NeurologistUpon arrival on-scene, the MSU stroke nurse, neurologist, and paramedic will liaise with local ambulance services to obtain initial clinical details and perform an initial assessment. The NIHSS will be performed by the neurologist, and this will be documented on standardized clinical records. Imaging will be assessed at the console available within the ambulance. If there is a decision to administer thrombolysis, the stroke neurologist and nurse will discuss treatment with the patient or next of kin, where appropriate and able, to acquire assent in a timely manner.
Telemedicine Assessment by Remote NeurologistTelemedicine Assessment by Remote NeurologistFollowing the initial assessment, the stroke nurse will activate the telemedicine video conference call and review the patient with the telemedicine neurologist. The telemedicine neurologist will perform a NIHSS with assistance from the stroke nurse, and this will be documented on the clinical records. Imaging will be evaluated remotely by the telemedicine neurologist. If there is a decision to administer thrombolysis, the stroke neurologist and nurse will discuss treatment with the patient or next of kin, where appropriate and able, to acquire assent in a timely manner.
Primary Outcome Measures
NameTimeMethod
Desirability of Outcome Ranking (DOOR) of: Safety, Scene-to-decision Treatment Times, and Resource EfficiencySee pre-specified outcome section for details

The odds that a random participant treated through a telemedicine assessment will have a more desirable DOOR scale outcome than a random participant treated by an onboard neurologist. Such a odds is referred to as the Win Ratio, as it reflects the odds of a random participant treated via telemedicine "winning" against a random participant treated via an onboard model in a direct one-to-one comparison.

The design evaluates, in order of importance: Safety, Scene-to-decision time metrics, Resource efficiency

If a participant in one treatment arm is achieving better safety than the comparator, this is defined as a "win" for that participant and a "loss" for the comparator. If there is no difference in safety, time to treatment decision is compared. If no clinically meaningful difference is observed, then resource utilization is compared. If there is no difference in resource utilization, the two participants are declared as tied for the overall outcome.

Secondary Outcome Measures
NameTimeMethod
On-scene to eyes-on-patient (for the neurologist)Time of Acute Assessment on the Mobile Stroke Unit (up to 2 hours from arrival on scene)
On-scene to imaging review by the neurologistTime of Acute Assessment on the Mobile Stroke Unit (up to 2 hours from arrival on scene)
On-scene to imagingTime of Acute Assessment on the Mobile Stroke Unit (up to 2 hours from arrival on scene)
90-Day mRS90 days (+/- 10 days from symptom onset)

Clinical outcomes for patients who receive thrombolysis on the MSU or are transferred to a comprehensive center for endovascular clot retrieval

On-scene to definitive decision makingTime of Acute Assessment on the Mobile Stroke Unit (up to 2 hours from arrival on scene)

Inclusive of the following: 1) Decision for thrombolysis, 2) Decision to refer for endovascular thrombectomy, 3) Decision to stand down case, or 4) Decision to transfer to stroke hospital (e.g. suspected stroke but unable to treat on MSU)

Trial Locations

Locations (1)

Royal Melbourne Hospital Mobile Stroke Unit

🇦🇺

Melbourne, Victoria, Australia

© Copyright 2025. All Rights Reserved by MedPath